Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer
Open Access
- 1 September 1996
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 74 (5) , 788-795
- https://doi.org/10.1038/bjc.1996.437
Abstract
We have analysed the expression of interleukin-2 receptor (IL-2R) on a panel of small-cell lung cancer (SCLC) cell lines. None of the 11 SCLC cell lines studied expressed detectable surface IL-2R alpha or beta chains by indirect immunofluorescence. Reverse transcriptase-polymerase chain reaction (RT-PCR) analyses indicated that only one out of 11 cell lines expressed detectable IL-2R beta mRNA while two expressed a weak positivity for IL-2R gamma. Five SCLC cell lines were transfected with the plasmid vector RSV.5 neo containing IL-2 cDNA coding sequence. Stable transfectants secreted biologically active IL-2 (ranging from 25 to 100 U ml-1 in the culture supernatant). IL-2 transfection did not produce significant modifications in the expression of surface molecules such as IL-2R alpha and beta chains, intercellular adhesion molecule-1 (ICAM-1), CD44, HLA class I and II or in IL-2R beta or gamma mRNA. More importantly, IL-2-transfected N592 and NCI H69 cell lines completely lost their tumorigenic potential in nude mice after subcutaneous injection, whereas experimental controls transfected with RSV.5 neo vector only, displayed an in vivo growth pattern identical to that of untransfected cells. In addition, in the N592 model, IL-2-producing N592 inhibited the growth of wild-type N592 injected at the same site, while injection of parental cells on the opposite side did not significantly affect the growth of wild-type tumour cells. Histopathological analysis of the rejection process of IL-2-transfected cells demonstrated the presence of MAC-1+, MAC-3+ macrophages and of RB68C5+ granulocytes, whereas T cells were undetectable and NK cells were scarcely represented. In addition, a reduction of the tumour blood vessels was observed. The possible relevance of these data for the development of vaccination strategies using cytokine-engineered tumour cells in SCLC is discussed.Keywords
This publication has 34 references indexed in Scilit:
- Cytokines and clinical gene therapyEuropean Journal of Immunology, 1995
- Interleukin 2 receptor expression and interleukin 2 localisation in human solid tumour cells in situ and in vitro: Evidence for a direct role in the regulation of tumour cell proliferationInternational Journal of Cancer, 1995
- Phase I Study of Transfected Cancer Cells Expressing the Interleukin-2 Gene Product in Limited Stage Small Cell Lung Cancer. University of Miami, Miami, FloridaHuman Gene Therapy, 1995
- Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?Immunology Today, 1994
- Human melanoma cells express a functional interleukin‐2 receptorInternational Journal of Cancer, 1993
- A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.The Journal of Experimental Medicine, 1992
- Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R.The Journal of Experimental Medicine, 1992
- Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cellsHuman Immunology, 1991
- Investigation of Interleukin 2 Receptors on Human Endothelial CellsGrowth Factors, 1991
- Influence of natural and recombinant interleukin 2 on endothelial cell arachidonate metabolism. Induction of de novo synthesis of prostaglandin H synthase.Journal of Clinical Investigation, 1988